SCHEMBL3522896

SCHEMBL3522896

ON=CC(c1ccccc1)(c1ccccc1)c1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.47
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
OPRK1 P41145 2/20 0.40
KCNH2 Q12809 2/20 0.40
ADRA1A P35348 1/20 0.40
KCNA3 P22001 2/20 0.37
TSHR P16473 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP19A1 P11511 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 2/20 0.36
SLC22A1 O15245 1/20 0.36
NR1I2 O75469 1/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
TRPM2 O94759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522893 1.00 KCNN4 (0.47) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL30456862 1.00 KCNN4 (0.47) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL3527440 0.78 KCNN4 (0.43) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL3522115 0.76 KCNN4 (0.52) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL27183395 0.76 KCNN4 (0.57) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL1871740 0.71 KCNN4 (0.47) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL6369689 0.69 KCNN4 (0.57) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL30114522 0.69 CYP3A4 (0.60) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL2131459 0.69 CYP3A4 (0.60) KCNN4HTR2AHTR2COPRK1KCNH2
SCHEMBL8157067 0.68 KCNN4 (0.61) KCNN4HTR2AHTR2COPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES ADIMABIO LLC (US) 2023-08-10 US claimed
WO-2018162426-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-09-13 WO claimed
US-20180136227-A1 Treatment and Diagnosis of Hereditary Xerocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-05-17 US claimed
EP-3307252-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2018-04-18 EP claimed
WO-2016202854-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS UNIVERSITE D'AIX-MARSEILLE (FR) 2016-12-22 WO claimed
EP-3106155-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2016-12-21 EP claimed
US-20250000887-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS AKIRABIO, INC. (US) 2025-01-02 US disclosed
US-11938143-B2 Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers AKIRABIO, INC. (US) 2024-03-26 US disclosed
WO-2023069529-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS AKIRABIO, INC. (US) 2023-04-27 WO disclosed
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA AKIRABIO INC (US) 2023-04-20 US disclosed
US-20230122664-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS CUSTOMERS BANK 2023-04-20 US disclosed
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC 2023-02-23 US disclosed
WO-2018162426-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-09-13 WO disclosed
US-20180136227-A1 Treatment and Diagnosis of Hereditary Xerocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-05-17 US disclosed
EP-3307252-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2018-04-18 EP disclosed
WO-2016202854-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS UNIVERSITE D'AIX-MARSEILLE (FR) 2016-12-22 WO disclosed
EP-3106155-A1 TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS Universite d'Aix Marseille (FR) 2016-12-21 EP disclosed
US-7709533-B2 Imines as ion channel modulators ICAGEN, INC. (US) 2010-05-04 US disclosed
US-20060178346-A1 Imines as ion channel modulators ICAGEN, INC. (US) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122664-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB KCNN4 3715/4885HTR2A 1234/4885HTR2C 1554/4885
US-11938143-B2 Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers TYMP, HBZ, CDA KCNN4 3745/4885HTR2A 1146/4885HTR2C 1463/4885
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES CACNA1G, CACNA1I, CACNG2 KCNN4 36/4885HTR2A 554/4885HTR2C 1046/4885
US-20250000887-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB KCNN4 3715/4885HTR2A 1234/4885HTR2C 1554/4885
US-20060178346-A1 Imines as ion channel modulators KCNN1, KCNN3, KCNN2 KCNN4 4/4885HTR2A 1212/4885HTR2C 1436/4885
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB KCNN4 3715/4885HTR2A 1234/4885HTR2C 1554/4885
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA HBB, HBZ, TYMP KCNN4 3612/4885HTR2A 1436/4885HTR2C 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.